We are pleased to announce that EDQM has granted us a new CEP for Buprenorphine. While Arevipharma’s active ingredient has been commercially available since 2010 under R1-CEP 2010-051 – Rev 01, we have updated our process with CEP 2021-298 – Rev 01 to meet the demands of the highly dynamic global Buprenorphine market.

The CEP for Buprenorphine HCl will follow shortly. Both products are also available with other worldwide registrations, e.g., in the USA, Canada, Australia, LATAM.